Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Peter Joel Hosein"'
Autor:
Iago de Castro Silva, Anna Bianchi, Nilesh U Deshpande, Prateek Sharma, Siddharth Mehra, Vanessa Tonin Garrido, Shannon Jacqueline Saigh, Jonathan England, Peter Joel Hosein, Deukwoo Kwon, Nipun B Merchant, Jashodeep Datta
Publikováno v:
eLife, Vol 11 (2022)
Background: Partial/complete pathologic response following neoadjuvant chemotherapy (NAC) in pancreatic cancer (PDAC) patients undergoing pancreatectomy is associated with improved survival. We sought to determine whether neutrophil-to-lymphocyte rat
Externí odkaz:
https://doaj.org/article/7e20e76ed4054b1da3daace7701f536d
Autor:
Iago de Castro Silva, Anna Bianchi, Nilesh U Deshpande, Prateek Sharma, Siddharth Mehra, Vanessa Tonin Garrido, Shannon Jacqueline Saigh, Jonathan England, Peter Joel Hosein, Deukwoo Kwon, Nipun B Merchant, Jashodeep Datta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::627e648526538ffdf895863e6466464f
https://doi.org/10.7554/elife.78921.sa2
https://doi.org/10.7554/elife.78921.sa2
Autor:
Erik Faber, Harris Krause, Phillip Walker, Peter Joel Hosein, Anthony Frank Shields, Heinz-Josef Lenz, Ajay Prakash, Sanjay Goel, Wolfgang Michael Korn, Matthew James Oberley, Claudio Luchini, Emil Lou
Publikováno v:
Journal of Clinical Oncology. 41:741-741
741 Background: While pancreatic adenocarcinoma (PDAC) remains a leading cause of cancer-related deaths, the highly aggressive PDAC subtype of undifferentiated sarcomatoid carcinoma (USC) remains poorly characterized as it comprises only 2-3% of all
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49d9a4b9c266657335693b35621ee5f5
https://doi.org/10.1200/jco.2023.41.4_suppl.741
https://doi.org/10.1200/jco.2023.41.4_suppl.741
Autor:
Brandon M, Huffman, Atrayee, Basu Mallick, Nora K, Horick, Andrea, Wang-Gillam, Peter Joel, Hosein, Michael A, Morse, Muhammad Shaalan, Beg, Janet E, Murphy, Sharon, Mavroukakis, Anjum, Zaki, Benjamin L, Schlechter, Hanna, Sanoff, Christopher, Manz, Brian M, Wolpin, Philip, Arlen, Jill, Lacy, James M, Cleary
Publikováno v:
JAMA Network Open. 6:e2249720
ImportanceTreatment options are limited for patients with advanced pancreatic ductal adenocarcinoma (PDAC) beyond first-line 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), with such individuals commonly being treated with gemci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11e3a21732ce98e608c1b59db5d68d0c
https://doi.org/10.1001/jamanetworkopen.2022.49720
https://doi.org/10.1001/jamanetworkopen.2022.49720
Autor:
Annika Lenz, Jia Zeng, Joanne Xiu, Sandra Algaze, Priya Jayachandran, Shivani Soni, Jae Ho Lo, Hiroyuki Arai, Wu Zhang, Pavel Brodskiy, Peter Joel Hosein, Benjamin Adam Weinberg, Emil Lou, Anthony Frank Shields, Richard M. Goldberg, John Marshall, Wolfgang Michael Korn, Heinz-Josef Lenz, Francesca Battaglin, Evanthia T. Roussos Torres
Publikováno v:
Journal of Clinical Oncology. 40:4048-4048
4048 Background: Claudins are transmembrane proteins which maintain the tight junction between cells. The stomach specific isoform, CLDN18 isoform 2 (CLDN18.2), is emerging as a promising treatment target because of high expression in GC cells, inclu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::012d2ba7caafdf8f8f83c7678ab4702d
https://doi.org/10.1200/jco.2022.40.16_suppl.4048
https://doi.org/10.1200/jco.2022.40.16_suppl.4048
Autor:
Roberto Enrique Ochoa, Say Salomon, Alexandra King, Peter Joel Hosein, Ernesto Prats Leon, Candace Gilbert, Daniel Guerra, Christopher James Chen, Scott Tromanhauser, James Chen
Publikováno v:
Journal of Clinical Oncology. 40:6595-6595
6595 Background: Value Based (VB) Care model has been growing in the primary care (PrC) Medicare population, its role in oncology and integration with VB PrC has not been well defined. Key initiatives in VB include reducing hospitalizations by multid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb288bc6a37b26307e039a16be4e6924
https://doi.org/10.1200/jco.2022.40.16_suppl.6595
https://doi.org/10.1200/jco.2022.40.16_suppl.6595
Autor:
Thomas J. George, Ji-Hyun Lee, Peter Joel Hosein, David L. DeRemer, Jonathan Alexander Chatzkel, Brian Hemendra Ramnaraign, Sherise C. Rogers, Merry Jennifer Markham, Karen Colleen Daily, Nkiruka Ezenwajiaku, Derek Li, Martina Cathryn Murphy, Aaron J Franke, Stephen Staal, Julia Lee Close, Dennie V. Jones, Carmen Joseph Allegra
Publikováno v:
Journal of Clinical Oncology. 40:3122-3122
3122 Background: BRCA1-Associated Protein 1 (BAP1) acts as a tumor suppressor and critical regulator of the cell cycle and DNA damage response (DDR). PARP inhibitors (PARPi) demonstrate synthetic lethality in BAP1 mutant (mBAP1) preclinical models, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::368fa23879f1c133a12e26d76c269856
https://doi.org/10.1200/jco.2022.40.16_suppl.3122
https://doi.org/10.1200/jco.2022.40.16_suppl.3122
Autor:
Haeseong Park, Aravind Sanjeevaiah, Peter Joel Hosein, Rutika Mehta, Ramon Jin, Patrick Grierson, Rama Suresh, Olivia Aranha, Nikolaos A. Trikalinos, Nusayba Ali Bagegni, Katrina Sophia Pedersen, Kian-Huat Lim, Andrew B. Nixon, Jason Mills, Ryan Fields, Benjamin R. Tan, Jingxia Liu, Amberly Brown, Andrea wang-gillam, A. Craig Lockhart
Publikováno v:
Journal of Clinical Oncology. 40:284-284
284 Background: Ramucirumab, a humanized monoclonal antibody targeting VEGFR2, is used for treatment of metastatic gastroesophageal adenocarcinoma after disease progression on first-line chemotherapy. Superior survival outcome is expected when combin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f53970c053ed0b394648cc3fc9327658
https://doi.org/10.1200/jco.2022.40.4_suppl.284
https://doi.org/10.1200/jco.2022.40.4_suppl.284
Multiomic characterization to reveal a distinct molecular landscape in young-onset pancreatic cancer
Autor:
Ifeanyichukwu Ogobuiro, Yasmine Baca, Phillip Walker, Gregory Wilson, Pat Gulhati, John Marshall, Rachna T. Shroff, Matthew James Oberley, Rebecca A Snyder, Alexander A. Parikh, Daniel Abbott, Hong Jin Kim, Shishir K. Maithel, David A. Kooby, Syed Ahmad, Peter Joel Hosein, Nipun B. Merchant, W. Michael Korn, David Spetzler, Jashodeep Datta
Publikováno v:
Journal of Clinical Oncology. 40:594-594
594 Background: Young-onset pancreatic cancer (YOPC; < 50 years at diagnosis) has been associated with male preponderance, extensive smoking history, and a trend towards improved survival compared with average-onset pancreatic cancer (AOPC; ≥70 yea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7416e63d21a4147b211cea86fbf120f9
https://doi.org/10.1200/jco.2022.40.4_suppl.594
https://doi.org/10.1200/jco.2022.40.4_suppl.594
Autor:
Sofia Palacio, Ikechukwu Immanuel Akunyili, Vinicius Ernani, Jessica Macintyre, Jaime R. Merchan, Terri Pollack, Isildinha Reis, Maria H. Restrepo, Caio Max S. Rocha Lima, Peter Joel Hosein
Publikováno v:
Journal of Clinical Oncology. 33:413-413
413 Background: The combination of nab-P and Gem improves survival compared to Gem alone in first-line therapy of metastatic pancreatic cancer. Efficacy data with this doublet in previously treated pts are scant. Our group presented preliminary resul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96010a2073efaa1792fdd002997383b5
https://doi.org/10.1200/jco.2015.33.3_suppl.413
https://doi.org/10.1200/jco.2015.33.3_suppl.413